公司实现营业总收入 1,043,768,680.27 元，较上年同期增长 29.52%；实现归属于母公司所有者的净利润 272,124,670.05 元，较上年同期增长 117.72%。报告期末，公司总资产 3,659,165,538.06 元，较期初增长 5.58%；归属于母公司的所有者权益 2,985,050,158.61 元，较期初增长 5.86%；归属于母公司所有者的每 股净资产 7.78 元，较期初增长 5.86%。 （二）上表中有关项目增减变动幅度达 30%以上的，增减变动的主要原因报告期内营业利润、利润总 额、归属于母公司所有者的净利润、归属于母公司所有者的扣除非经常性损益的净利润及基本每股收益 较上年同期显著增长，主要原因为： 1、随着骨科耗材国家集采常态化推进，公司依托完善的渠道覆盖网络与丰富的产品体系，产品销量稳 步提升，国内业务规模与市场份额持续扩大，推动盈利水平稳步提升。 2、公司持续推进国际化战略，依托达到国际先进水平的产品技术与质量标准，在国际市场实现了业务 的持续拓展与突破，海外营收稳步提升，为公司整体业绩增长提供重要支撑。 证券之星消息，春立医疗近日即将发布2025年年报，根据 ...

证券之星消息，截至2026年2月9日收盘，春立医疗(688236)报收于23.0元，下跌0.35%，换手率0.53%， 成交量1.52万手，成交额3498.88万元。 2月9日的资金流向数据方面，主力资金净流出63.27万元，占总成交额1.81%，游资资金净流入391.14万 元，占总成交额11.18%，散户资金净流出327.87万元，占总成交额9.37%。 春立医疗融资融券信息显示，融资方面，当日融资买入524.38万元，融资偿还376.73万元，融资净买入 147.65万元。融券方面，融券卖出400.0股，融券偿还0.0股，融券余量800.0股，融券余额1.84万元。融 资融券余额4854.82万元。 近5日融资融券数据一览见下表： | 日期 | 涨跌幅 | | 融资余额(元) 融资净买入(元) 融券余量(股) | | (品)用品要求量 | 融资融券余额(元) | | --- | --- | --- | --- | --- | --- | --- | | 2026-02-09 | -0.35% | 4852.98万 | 147.65万 | 800.0 | 400.0 | 4854.82万 | | 2026 ...

证券之星消息，截至2026年2月4日收盘，春立医疗(688236)报收于23.03元，下跌1.24%，换手率 0.74%，成交量2.14万手，成交额4912.14万元。 2月4日的资金流向数据方面，主力资金净流入283.14万元，占总成交额5.76%，游资资金净流入216.54 万元，占总成交额4.41%，散户资金净流出499.68万元，占总成交额10.17%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2026-02-04 | 23.03 | -1.24% | 283.14万 | 5.76% | 216.54万 | 4.41% | -499.68万 | -10.17% | | 2026-02-03 | 23.32 | 0.95% | 63.18万 | 1.35% | -104.25万 | -2.23% | 41.07万 | 0.88% | | 2026-02-02 | 23.10 | - ...

证券之星消息，截至2026年2月2日收盘，春立医疗(688236)报收于23.1元，下跌1.7%，换手率1.11%， 成交量3.21万手，成交额7586.53万元。 2月2日的资金流向数据方面，主力资金净流入93.69万元，占总成交额1.23%，游资资金净流入168.14万 元，占总成交额2.22%，散户资金净流出261.83万元，占总成交额3.45%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 春立医疗2025年三季报显示，前三季度公司主营收入7.56亿元，同比上升48.75%；归母净利润1.92亿 元，同比上升213.21%；扣非净利润1.81亿元，同比上升311.07%；其中2025年第三季度，公司单季度主 营收入2.68亿元，同比上升109.51%；单季度归母净利润7706.19万元，同比上升531.12%；单季度扣非 净利润7451.86万元，同比上升439.4%；负债率15.65%，投资收益321.7万元，财务费用-972.34万元，毛 利率67.27%。春立医疗（688236）主营业务：植入性骨科医疗器械的研发、生产与销售。 该股最近90天内共有6家机构给出评级，买入评级6家； ...

证券之星消息，截至2026年1月29日收盘，春立医疗(688236)报收于25.25元，上涨0.12%，换手率 0.86%，成交量2.48万手，成交额6374.46万元。 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 春立医疗2025年三季报显示，前三季度公司主营收入7.56亿元，同比上升48.75%；归母净利润1.92亿 元，同比上升213.21%；扣非净利润1.81亿元，同比上升311.07%；其中2025年第三季度，公司单季度主 营收入2.68亿元，同比上升109.51%；单季度归母净利润7706.19万元，同比上升531.12%；单季度扣非 净利润7451.86万元，同比上升439.4%；负债率15.65%，投资收益321.7万元，财务费用-972.34万元，毛 利率67.27%。春立医疗（688236）主营业务：植入性骨科医疗器械的研发、生产与销售。 该股最近90天内共有6家机构给出评级，买入评级6家；过去90天内机构目标均价为31.9。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于 ...

春立医疗融资融券信息显示，融资方面，当日融资买入740.78万元，融资偿还656.02万元，融资净买入 84.76万元。融券方面，融券卖出0.0股，融券偿还0.0股，融券余量1.24万股，融券余额31.99万元。融资 融券余额4090.05万元。 证券之星消息，截至2026年1月27日收盘，春立医疗(688236)报收于25.8元，下跌3.04%，换手率 0.87%，成交量2.5万手，成交额6458.86万元。 1月27日的资金流向数据方面，主力资金净流出13.76万元，占总成交额0.21%，游资资金净流入263.09 万元，占总成交额4.07%，散户资金净流出249.34万元，占总成交额3.86%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 春立医疗2025年三季报显示，前三季度公司主营收入7.56亿元，同比上升48.75%；归母净利润1.92亿 元，同比上升213.21%；扣非净利润1.81亿元，同比上升311.07%；其中2025年第三季度，公司单季度主 营收入2.68亿元，同比上升109.51%；单季度归母净利润7706.19万元，同比上升531.12%；单季度扣非 净利润7451. ...

近5日资金流向一览见下表： 证券之星消息，截至2026年1月26日收盘，春立医疗(688236)报收于26.61元，下跌1.11%，换手率 0.79%，成交量2.28万手，成交额6098.04万元。 1月26日的资金流向数据方面，主力资金净流出372.24万元，占总成交额6.1%，游资资金净流出24.28万 元，占总成交额0.4%，散户资金净流入396.52万元，占总成交额6.5%。 春立医疗2025年三季报显示，前三季度公司主营收入7.56亿元，同比上升48.75%；归母净利润1.92亿 元，同比上升213.21%；扣非净利润1.81亿元，同比上升311.07%；其中2025年第三季度，公司单季度主 营收入2.68亿元，同比上升109.51%；单季度归母净利润7706.19万元，同比上升531.12%；单季度扣非 净利润7451.86万元，同比上升439.4%；负债率15.65%，投资收益321.7万元，财务费用-972.34万元，毛 利率67.27%。春立医疗（688236）主营业务：植入性骨科医疗器械的研发、生产与销售。 该股最近90天内共有8家机构给出评级，买入评级8家；过去90天内机构目标均价为31 ...

Core Viewpoint - Spring Medical (688236) shows significant growth in revenue and net profit for the first three quarters of 2025, indicating strong performance in the orthopedic medical device sector [2] Financial Performance - For the first three quarters of 2025, the company reported a main revenue of 756 million yuan, an increase of 48.75% year-on-year [2] - The net profit attributable to shareholders reached 192 million yuan, up 213.21% year-on-year [2] - The non-recurring net profit was 181 million yuan, reflecting a substantial increase of 311.07% year-on-year [2] - In Q3 2025 alone, the company achieved a main revenue of 268 million yuan, a remarkable rise of 109.51% year-on-year [2] - The quarterly net profit attributable to shareholders was 77.06 million yuan, soaring by 531.12% year-on-year [2] - The quarterly non-recurring net profit stood at 74.52 million yuan, an increase of 439.4% year-on-year [2] - The company's debt ratio is reported at 15.65%, with investment income of 3.217 million yuan and financial expenses of -9.7234 million yuan [2] - The gross profit margin is noted at 67.27% [2] Market Activity - As of January 23, 2026, the stock closed at 26.91 yuan, with a 1.17% increase [1] - The turnover rate was 0.73%, with a trading volume of 21,200 hands and a transaction amount of 57.25 million yuan [1] - On January 23, the net outflow of main funds was 145,000 yuan, accounting for 0.25% of the total transaction amount [1] - Retail investors saw a net inflow of 3.0137 million yuan, representing 5.26% of the total transaction amount [1] - Over the past 90 days, 8 institutions have rated the stock, all giving a buy rating, with an average target price of 31.7 yuan [2]

Core Viewpoint - Spring Medical (688236) shows strong financial performance with significant year-on-year growth in revenue and net profit, indicating a positive outlook for the company in the orthopedic medical device sector [2]. Financial Performance - For the first three quarters of 2025, Spring Medical reported a main revenue of 756 million yuan, an increase of 48.75% year-on-year [2]. - The net profit attributable to shareholders reached 192 million yuan, up 213.21% year-on-year [2]. - The net profit excluding non-recurring items was 181 million yuan, reflecting a substantial increase of 311.07% year-on-year [2]. - In Q3 2025 alone, the company achieved a main revenue of 268 million yuan, a remarkable rise of 109.51% year-on-year [2]. - The quarterly net profit attributable to shareholders was 77.06 million yuan, soaring by 531.12% year-on-year [2]. - The quarterly net profit excluding non-recurring items was 74.52 million yuan, up 439.4% year-on-year [2]. - The company's debt ratio stands at 15.65%, with investment income of 3.217 million yuan and financial expenses of -9.7234 million yuan [2]. - The gross profit margin is reported at 67.27% [2]. Market Activity - As of January 22, 2026, Spring Medical's stock closed at 26.6 yuan, down 0.64%, with a turnover rate of 0.72% and a trading volume of 20,700 hands, amounting to a transaction value of 55.49 million yuan [1]. - On January 22, the net outflow of main funds was 4.5364 million yuan, accounting for 8.18% of the total transaction value, while retail investors saw a net inflow of 1.1627 million yuan, representing 2.1% of the total [1]. Analyst Ratings - In the last 90 days, 8 institutions have rated Spring Medical with a "buy" recommendation, and the average target price set by these institutions is 31.7 yuan [3].

Core Viewpoint - Spring Medical (688236) shows strong financial performance with significant year-on-year growth in revenue and net profit, indicating a positive outlook for the company in the orthopedic medical device sector [2]. Financial Performance - For the first three quarters of 2025, Spring Medical reported a main revenue of 756 million yuan, an increase of 48.75% year-on-year [2]. - The net profit attributable to shareholders reached 192 million yuan, up 213.21% year-on-year [2]. - The non-recurring net profit was 181 million yuan, reflecting a substantial increase of 311.07% year-on-year [2]. - In Q3 2025 alone, the company achieved a main revenue of 268 million yuan, a remarkable rise of 109.51% year-on-year [2]. - The net profit for Q3 was 77.06 million yuan, showing a staggering increase of 531.12% year-on-year [2]. - The non-recurring net profit for Q3 was 74.52 million yuan, up 439.4% year-on-year [2]. - The company's debt ratio stands at 15.65%, with investment income of 3.217 million yuan and financial expenses of -9.7234 million yuan [2]. - The gross profit margin is reported at 67.27% [2]. Market Activity - As of January 14, 2026, Spring Medical's stock closed at 26.66 yuan, with an increase of 1.18% [1]. - The turnover rate was 1.95%, with a trading volume of 56,100 hands and a transaction amount of 154 million yuan [1]. - On January 14, the net inflow of main funds was 21.38 million yuan, accounting for 13.92% of the total transaction amount [1]. - Retail investors experienced a net outflow of 18.21 million yuan, representing 11.86% of the total transaction amount [1]. Analyst Ratings - In the last 90 days, 8 institutions have given buy ratings for Spring Medical, with a target average price of 31.7 yuan [3].